Literature DB >> 21912416

Chemotherapy: Is adjuvant chemotherapy an option for stage II colon cancer?

Christophe Tournigand, Aimery de Gramont.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21912416     DOI： 10.1038/nrclinonc.2011.139

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.

Authors:  Michael J O'Connell; Ian Lavery; Greg Yothers; Soonmyung Paik; Kim M Clark-Langone; Margarita Lopatin; Drew Watson; Frederick L Baehner; Steven Shak; Joffre Baker; J Wayne Cowens; Norman Wolmark
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

2.  Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.

Authors:  Donna Niedzwiecki; Monica M Bertagnolli; Robert S Warren; Carolyn C Compton; Nancy E Kemeny; Al Bowen Benson; S Gail Eckhardt; Steven Alberts; Gity N Porjosh; David J Kerr; Anthony Fields; Philippe Rougier; J Marc Pipas; Joel H Schwartz; James Atkins; Mark O'Rourke; Michael C Perry; Richard M Goldberg; Robert J Mayer; Thomas A Colacchio
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

3.  Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.

Authors:  Greg Yothers; Michael J O'Connell; Carmen J Allegra; J Philip Kuebler; Linda H Colangelo; Nicholas J Petrelli; Norman Wolmark
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

4.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

Authors:  Daniel J Sargent; Silvia Marsoni; Genevieve Monges; Stephen N Thibodeau; Roberto Labianca; Stanley R Hamilton; Amy J French; Brian Kabat; Nathan R Foster; Valter Torri; Christine Ribic; Axel Grothey; Malcolm Moore; Alberto Zaniboni; Jean-Francois Seitz; Frank Sinicrope; Steven Gallinger
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

5.  Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

Authors:  Erin S O'Connor; David Yu Greenblatt; Noelle K LoConte; Ronald E Gangnon; Jinn-Ing Liou; Charles P Heise; Maureen A Smith
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

Review 6.  Current issues in adjuvant treatment of stage II colon cancer.

Authors:  Thierry André; Daniel Sargent; Josep Tabernero; Michael O'Connell; Marc Buyse; Alberto Sobrero; Jean-Louis Misset; Corrado Boni; Aimery de Gramont
Journal:  Ann Surg Oncol       Date:  2006-04-14       Impact factor: 5.344

7.  Revised TN categorization for colon cancer based on national survival outcomes data.

Authors:  Leonard L Gunderson; John Milburn Jessup; Daniel J Sargent; Frederick L Greene; Andrew K Stewart
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

8.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

Authors:  Thierry André; Corrado Boni; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Andrea Bonetti; Philip Clingan; John Bridgewater; Fernando Rivera; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

9.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.

Authors:  Richard Gray; Jennifer Barnwell; Christopher McConkey; Robert K Hills; Norman S Williams; David J Kerr
Journal:  Lancet       Date:  2007-12-15       Impact factor: 79.321
  9 in total
  10 in total

1.  The role of adjuvant chemotherapy in stage II colorectal cancer patients.

Authors:  Hung-Hsin Lin; Yu-Yao Chang; Jen-Kou Lin; Jeng-Kai Jiang; Chun-Chi Lin; Yuan-Tzu Lan; Shung-Haur Yang; Huann-Sheng Wang; Wei-Shone Chen; Tzu-Chen Lin; Shih-Ching Chang
Journal:  Int J Colorectal Dis       Date:  2014-07-15       Impact factor: 2.571

2.  Impact of Lymphovascular Invasion in Patients With Stage II Colorectal Cancer: A Propensity Score-matched Study.

Authors:  Masahiro Kataoka; Yasumitsu Hirano; Toshimasa Ishii; Hiroka Kondo; Masahiro Asari; Shintaro Ishikawa; Atsuko Kataoka; Takatsugu Fujii; Satoshi Shimamura; Shigeki Yamaguchi
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

3.  CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.

Authors:  Piero Dalerba; Debashis Sahoo; Soonmyung Paik; Xiangqian Guo; Greg Yothers; Nan Song; Nate Wilcox-Fogel; Erna Forgó; Pradeep S Rajendran; Stephen P Miranda; Shigeo Hisamori; Jacqueline Hutchison; Tomer Kalisky; Dalong Qian; Norman Wolmark; George A Fisher; Matt van de Rijn; Michael F Clarke
Journal:  N Engl J Med       Date:  2016-01-21       Impact factor: 91.245

Review 4.  Treatment of colorectal cancer in older patients.

Authors:  Riccardo A Audisio; Demetris Papamichael
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-10-09       Impact factor: 46.802

5.  The prognostic importance of miR-21 in stage II colon cancer: a population-based study.

Authors:  S Kjaer-Frifeldt; T F Hansen; B S Nielsen; S Joergensen; J Lindebjerg; F B Soerensen; R dePont Christensen; A Jakobsen
Journal:  Br J Cancer       Date:  2012-09-25       Impact factor: 7.640

6.  hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy.

Authors:  Leonardo Muratori; Giulia Petroni; Lorenzo Antonuzzo; Luca Boni; Jessica Iorio; Elena Lastraioli; Gianluca Bartoli; Luca Messerini; Francesco Di Costanzo; Annarosa Arcangeli
Journal:  Onco Targets Ther       Date:  2016-10-14       Impact factor: 4.147

7.  NCAPH plays important roles in human colon cancer.

Authors:  Liang Yin; Li-Ping Jiang; Qiu-Shuo Shen; Qiu-Xia Xiong; Xiao Zhuo; Long-Long Zhang; Hai-Jing Yu; Xiang Guo; Ying Luo; Jian Dong; Qing-Peng Kong; Cui-Ping Yang; Yong-Bin Chen
Journal:  Cell Death Dis       Date:  2017-03-16       Impact factor: 8.469

8.  ADCK1 activates the β-catenin/TCF signaling pathway to promote the growth and migration of colon cancer cells.

Authors:  Yong Ji; Yiqian Liu; Changchun Sun; Lijiang Yu; Zhao Wang; Xu Du; Wu Yang; Chenggong Zhang; Chunmu Tao; Jianjiang Wang; Xi Yang; Sun Di; Yufeng Huang
Journal:  Cell Death Dis       Date:  2021-04-06       Impact factor: 8.469

9.  Copy-number intratumor heterogeneity as high-risk feature of stage II colon cancer†.

Authors:  Tom van den Bosch; Daniël M Miedema; Louis Vermeulen
Journal:  J Pathol       Date:  2022-05-23       Impact factor: 9.883

Review 10.  Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer: a systematic review and meta-analysis.

Authors:  Hang Yuan; Quanjin Dong; Bo'an Zheng; Xinye Hu; Jian-Bo Xu; Shiliang Tu
Journal:  Oncotarget       Date:  2017-07-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.